Determining Treatment Options for Select Subsets of Neuroendocrine Tumors

Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Prospective models show a drop in the cost of running sentinel lymph node assessments when artificial intelligence is used.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

Recent findings identified that overall and cancer-specific mortality risks were lowered in patients who used antidepressants following a diagnosis with hepatocellular carcinoma compared with patients that did not.

In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.